Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05613946 · ClinicalTrials.gov registry record · Phase 1
Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT05613946: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT05613946 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05613946, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this research is to determine the preferred microbubble agent (Lumason®, Optison®, and Definity®) for lymphatic channel visualization by ultrasound. This research will also evaluate the utility of preoperative high-frequency B-mode ultrasound with contrast-enhanced ultrasound for presurgical planning, and ultrasound shear wave elastography for assessing treatment response at 6-month follow up.
Interventions
- DRUG Lumason
- DRUG Optison
- DRUG Definity
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-12-15 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05613946
The ClinicalTrials.gov registry entry for NCT05613946 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lumason is the first listed.
NCT05613946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05613946 about?
NCT05613946 is a clinical study titled "Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema". The purpose of this research is to determine the preferred microbubble agent (Lumason®, Optison®, and Definity®) for lymphatic channel visualization by ultrasound. This research will also evaluate the utility of preoperative high-frequency B-mode ultrasound with contrast-enhanced ultrasound for pres...
What is the current status of trial NCT05613946?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2022-12-15. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT05613946?
The interventions under investigation include: Lumason (DRUG), Optison (DRUG), Definity (DRUG).
Who is sponsoring clinical trial NCT05613946?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.